Achieve Life Sciences (ACHV) Non-Current Assets (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Non-Current Assets came in at $2.0 million in Q1 2026, down 13.32% YoY from $2.4 million in Q1 2025, and up 7.52% on a QoQ basis from $1.9 million in Q4 2025.
Achieve Life Sciences (ACHV) Non-Current Assets (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Non-Current Assets data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 13.32% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (down 13.31% YoY) and the FY2025 annual result came in at $1.9 million, down 12.23% from the prior year.
- Non-Current Assets climbed to $2.0 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $2.9 million in Q1 2022 to a low of $1.9 million in Q4 2025.
- A 5-year average of $2.4 million and a median of $2.4 million in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 1.64% in 2025, down 16.88% in 2025.
- Tracing ACHV's Non-Current Assets over 5 years: stood at $2.6 million in 2022, then dropped by 9.54% to $2.4 million in 2023, then declined by 9.33% to $2.2 million in 2024, then dropped by 12.23% to $1.9 million in 2025, then gained by 7.52% to $2.0 million in 2026.
- The last three Non-Current Assets figures came in at $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 2.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.15 Mn |
| Mar 31, 2026 | 2.04 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 2.27 Mn |
| Mar 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 2.39 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.54 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 2.64 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Jun 30, 2022 | 2.84 Mn |
| Mar 31, 2022 | 2.92 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 3.07 Mn |